Drug Profile
Amikacin liposomal inhaled - Insmed
Alternative Names: ALIS; Amikacin Liposome Inhalation Suspension; Arikace; ARIKAYCE; Liposomal amikacin for inhalation; SLIT™ Amikacin; TR-02Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Transave
- Developer Insmed; National Institute of Allergy and Infectious Diseases; Oregon Health & Science University; University of Texas Health Science Center at Tyler
- Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Nontuberculous mycobacterium infections
- Preregistration Cystic fibrosis-associated respiratory tract infections
- Phase II Bronchiectasis
Most Recent Events
- 31 Dec 2023 Insmed has patent protection for amikacin liposomal inhaled in Europe, Japan, China, Korea, Australia, and India
- 31 Dec 2023 Insmed has patents pending that relate to the ARIKAYCE composition and/or its use in treating various pulmonary disorders, including NTM lung disease in multiple countries
- 05 Sep 2023 Efficacy and adverse events data from the phase III ARISE trial in Nontuberculous mycobacterium infections released by Insmed